Summary
This phase 3 randomised controlled trial, published in The Lancet Respiratory Medicine in 2022, assessed the efficacy and safety profile of tixagevimab–cilgavimab, a long-acting monoclonal antibody combination administered intramuscularly for early outpatient treatment of COVID-19. As a double-blind, placebo-controlled design with international participation, the trial aimed to evaluate whether this therapeutic approach could reduce clinical progression in symptomatic patients treated outside hospital settings. The findings contribute to the evidence base for monoclonal antibody therapies in early COVID-19 management during the pandemic response period.
UK applicability
As a global phase 3 trial with likely United Kingdom participant centres (suggested by lead author affiliation patterns and international scope), the results would be directly applicable to NHS outpatient COVID-19 treatment pathways and procurement decisions for monoclonal antibody therapeutics during the 2022 pandemic period.
Key measures
Clinical efficacy endpoints (as suggested by phase 3 trial design), safety and tolerability profiles, and adverse events associated with intramuscular monoclonal antibody administration
Outcomes reported
The study evaluated efficacy and safety of intramuscular tixagevimab–cilgavimab (a long-acting monoclonal antibody combination) versus placebo for early outpatient treatment of COVID-19. Primary outcomes as suggested by the title include clinical efficacy measures and adverse event monitoring in a phase 3 randomised controlled trial.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.